About
ArkVax develops glycoconjugate vaccines for animals using genetically engineered bacterial cells to produce glycan-based vaccines that enhance potency and breadth while targeting antimicrobial resistance and zoonotic disease protection.
Explore ArkVax's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.